Search

Copyright of Praxis (16618157) is the property of Aerzteverlag medinfo AG and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Praxis (16618157) is the property of Aerzteverlag medinfo AG and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Praxis (16618157) is the property of Aerzteverlag medinfo AG and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary renal disease. Continuous growth of multiple cysts in both kidneys leads to progressive renal enlargement and ultimately to loss of kidney function. Treatment until recently has been largely symptomatic. The V2-receptor antagonist tolvaptan is the first specific treatment with proven efficacy to reduce cyst growth and to retard kidney function loss. Tolvaptan has become available for the treatment of ADPKD in Switzerland in 2016, but given its high costs and adverse effects on the one side and the considerable variability in progression and prognosis of ADPKD on the other, prescription of tolvaptan has been limited to patients with rapidly progressive disease. Criteria for rapid progression have been listed by the Federal Office of Public Health on the list of pharmaceutical specialties. This article gives recommendations on how to implement these criteria in the clinical routine, with a focus on imaging methods that are used to determine total kidney volume (TKV). [ABSTRACT FROM AUTHOR]

Copyright of Praxis (16618157) is the property of Aerzteverlag medinfo AG and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

A 73-year-old otherwise healthy male patient presented to his family doctor with unspecific lower urinary tract symptoms. A) Retrorectal lymph node metastasis of the prostate cancer b) Anterior sacral meningocele c) Colorectal carcinoma d) Tailgut cyst e) Leiomyosarcoma Conclusion • The pararectal cystic lesion is most likely a tailgut cyst and did not show any signs of malignant transformation. An additional rectal endosonography showed a cystic lesion of 13 mm close to the rectum and calcifications of the prostatic adenocarcinoma. [Extracted from the article]